Open

Study of LY3537982 and Immunotherapy with or Without Chemotherapy for People with Non-Small Cell Lung Cancer

The purpose of this study is to see if adding LY3537982 to standard cancer treatments works better than just using the standard treatments alone for people with advanced non-small cell lung cancer (NSCLC) who have not yet been treated.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

- Treatment will be given in a 21-day cycle. - You will take the investigational drug in pill form, twice a day. - You will be asked to keep a diary of your medication and health. - During visits, your vital signs will be checked. - You will also be asked about your physical well-being.

Incentives

Study Medication

In-person visits:
All

Phone or online visits:
none

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

Disease must have KRAS muation
Life expectancy of 12 weeks or greater
Ability to swallow pills

Not eligible if:

Prior therapy for cancer
Known central nervous system tumors

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-2028

ClinicalTrials.gov

NCT06119581

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.